Comparison · NCT02285153-b3f949c8
Acetylsalicylic Acid Lysinate vs 0.9% Sodium-chloride Solution: Intensive Care Unit Mortality
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Acetylsalicylic Acid Lysinate vs 0.9% Sodium-chloride Solution: Intensive Care Unit Mortality. Trial comparisons, record NCT02285153-b3f949c8. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02285153-b3f949c8
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.286 | 0.0822 | 0.641 | wilson | |
| Risk in group 2 | 0.125 | 0.0224 | 0.471 | wilson | |
| Risk difference, group 1 minus group 2 | 0.161 | -0.241 | 0.531 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.29 | 0.26 | 20.1 | log | |
| Odds ratio, group 1 over group 2 | 2.8 | 0.196 | 40.1 | log | |
| Number needed to treat, for one more participant with the outcome on Acetylsalicylic Acid Lysinate than on 0.9% Sodium-chloride Solution | 6.22 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Acetylsalicylic Acid Lysinate | 100mg Acetylsalicylic Acid~Acetylsalicylic acid lysinate: 100mg intravenously administered Acetylsalicylic Acid lysinate per day | 2 | 7 | OG000 |
| Group 2 | 0.9% Sodium-chloride Solution | 0.9% sodium-chloride solution~0.9% sodium-chloride solution: Placebo, intravenously administered, daily | 1 | 8 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Intensive Care Unit Mortality
- Description
- Mortality of patients during their intensive care unit stay, 90 day mortality, potentially longer
- Time frame
- up to 90 days after inclusion
- Population
Source ClinicalTrials.gov
Trial
- Title
- Does Acetylsalicylic Acid Reduce the Mortality of Patients Admitted to an Intensive Care Unit
- NCT number
- NCT02285153
- Phases
- PHASE3
- Conditions
- Critical Illness
- Interventions
- Acetylsalicylic acid lysinate, 0.9% sodium-chloride solution
- Lead sponsor
- Medical University of Vienna
- Results first posted
- 2019-12-18
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02285153?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02285153-b3f949c8